List of Excipients in Branded Drug PREVACID 24 HR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6002	D&C RED NO. 28
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6002	FD&C BLUE NO. 1
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6002	FD&C GREEN NO. 3
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6002	FD&C RED NO. 40
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6002	GELATIN

PREVACID 24 HR Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 24, 2026

PREVACID 24 HR is a 15 mg delayed-release lansoprazole capsule for OTC treatment of frequent heartburn. Its commercial value depends less on active-ingredient exclusivity, which has expired, than on enteric-release performance, capsule technology, brand recognition, retail distribution, and consumer-facing formulation improvements. The primary opportunity is to develop lower-cost or differentiated lansoprazole products that preserve acid protection through the stomach while improving capsule stability, excipient acceptability, packaging, and consumer convenience.

What is PREVACID 24 HR and how is it formulated?

PREVACID 24 HR contains lansoprazole, a proton pump inhibitor, at a 15 mg dose. The product is administered once daily for 14 consecutive days and is intended for adults with frequent heartburn, generally defined in the labeling as heartburn occurring two or more days per week (FDA, 2024a).

The dosage form is a delayed-release capsule. Lansoprazole is acid-labile, so the formulation must prevent release in the stomach and deliver the drug into the higher-pH environment of the small intestine.

Core formulation architecture

The product uses an encapsulated multiparticulate system rather than a conventional immediate-release powder-filled capsule. The likely functional architecture is:

1. Inert starter pellets or sugar spheres.
2. A drug-containing layer containing lansoprazole.
3. Protective subcoats that limit drug degradation and control interactions between lansoprazole and acidic or reactive excipients.
4. An enteric polymer layer that remains intact in gastric fluid.
5. A hard gelatin capsule containing the coated pellets.

The FDA labeling identifies inactive ingredients that include sugar, hypromellose, low-substituted hydroxypropyl cellulose, methacrylic acid copolymer, talc, polyethylene glycol, polysorbate 80, colloidal silicon dioxide, titanium dioxide, gelatin, and colorants, although the precise excipient list can vary by labeler, manufacturing site, and product presentation (FDA, 2024a).

Formulation element	Commercial or technical function
Sugar spheres	Pellet substrate and dose distribution
Hypromellose	Film former and protective coating component
Low-substituted hydroxypropyl cellulose	Binder, disintegrant, or coating support
Methacrylic acid copolymer	Enteric protection
Talc	Anti-tacking and coating-process aid
Polyethylene glycol	Plasticizer
Polysorbate 80	Wetting or dispersion aid
Colloidal silicon dioxide	Flow and moisture-control aid
Gelatin	Capsule shell
Titanium dioxide and colorants	Opacity and product identification

The commercial objective is not simply to replicate the excipient list. A competitive manufacturer must reproduce dissolution, acid resistance, release timing, assay, impurity control, and stability while avoiding unnecessary formulation similarity that could increase manufacturing cost or expose the product to avoidable supply-chain constraints.

What excipients are most important to PREVACID 24 HR performance?

The enteric coating is the highest-value excipient system. Lansoprazole must remain protected during gastric exposure and release rapidly after the dosage form reaches the intestine. The principal technical risks are premature release, incomplete release, coating defects, drug degradation, and variability across pellet populations.

Enteric polymer selection

Methacrylic acid copolymers are widely used for pH-dependent release. Commercial alternatives include different grades of methacrylic acid-ethyl acrylate copolymers, cellulose acetate phthalate, hypromellose phthalate, and polyvinyl acetate phthalate. Each alternative changes:

• Minimum dissolution pH.
• Coating weight.
• Mechanical strength.
• Moisture permeability.
• Processing temperature.
• Residual solvent profile.
• Release variability.

A formulation that uses a higher-pH enteric polymer could delay release beyond the target intestinal region. A lower-pH polymer could increase the risk of gastric release. Substitution therefore requires comparative dissolution testing in acid and buffer stages, not only assay and stability testing.

Protective subcoats

Lansoprazole is sensitive to acidic conditions and can be affected by contact with incompatible excipients. A subcoat between the drug layer and the enteric layer can reduce migration, improve adhesion, and separate the active ingredient from acidic polymer components.

Potential subcoat strategies include:

• Hypromellose-based films.
• Neutral polymer barriers.
• Low-moisture coating systems.
• Multiple thin layers rather than one high-weight coating.
• Functional barrier coatings that reduce interaction with enteric polymers.

The opportunity is strongest where a manufacturer can reduce coating weight or processing time while maintaining equivalent acid resistance and intestinal release.

Plasticizers and surfactants

Polyethylene glycol and related plasticizers improve coating flexibility but can increase water permeability or migration if improperly selected. Polysorbate 80 can improve dispersion and wetting but may introduce oxidation or compatibility considerations.

A practical excipient-screening program should assess:

• Peroxide content.
• Water activity.
• Hygroscopicity.
• Interaction with lansoprazole degradation products.
• Coating adhesion.
• Pellet friability.
• Dissolution after accelerated aging.

What FDA regulatory status applies to PREVACID 24 HR?

PREVACID 24 HR is an OTC drug product approved through an FDA new drug application rather than a prescription generic approval. The product is labeled for short-term self-treatment of frequent heartburn in adults and has age, duration, and warning limitations (FDA, 2024a).

FDA milestones and regulatory pathway

Regulatory issue	Relevance to PREVACID 24 HR
Active ingredient	Lansoprazole
Strength	15 mg
Route	Oral
Dosage form	Delayed-release capsule
Regulatory category	OTC drug product
Use	Frequent heartburn
Standard regimen	One capsule daily for 14 days
Pediatric scope	Not a general pediatric self-care product
Key quality requirement	Delayed-release performance and stability

A follow-on product can pursue several routes:

1. ANDA route: Appropriate when referencing an eligible listed prescription drug and meeting generic requirements.
2. 505(b)(2) NDA route: Potentially relevant for a materially different dosage form, delivery system, or formulation supported by published data and bridging studies.
3. OTC NDA or monograph-based strategy: Relevant where the proposed product fits applicable OTC conditions and labeling requirements.
4. Private-label or authorized-brand strategy: Commercially attractive for retailers seeking a store-brand product with equivalent therapeutic positioning.

The regulatory route depends on whether the sponsor is copying an existing approved product, changing the dosage form, or pursuing a differentiated delivery system.

What patents protect PREVACID 24 HR?

The original lansoprazole composition, formulation, and use patents associated with PREVACID have expired or lost practical exclusivity. The current OTC product does not have the same patent-based market protection that supported the original prescription launch.

The original PREVACID franchise was linked to Takeda Pharmaceuticals and earlier TAP Pharmaceutical Products. Historical patents covered lansoprazole compositions, pharmaceutical formulations, and treatment methods. Patent and regulatory exclusivity for the prescription product no longer blocks ordinary generic lansoprazole competition.

Orange Book status

PREVACID 24 HR is an OTC product, not a currently marketed prescription product relying on an Orange Book-listed NDA for commercial exclusivity. The FDA Orange Book is principally used for approved prescription and certain other drug products with therapeutic-equivalence listings (FDA, 2024b).

The practical implications are:

• An OTC sponsor generally does not control the market through active Orange Book patent listings in the same manner as a prescription NDA holder.
• Paragraph IV litigation is primarily associated with ANDAs that reference an Orange Book-listed drug.
• A competing OTC lansoprazole product would more likely face formulation, trade dress, trademark, manufacturing, and regulatory issues than a direct Orange Book patent blockade.
• New patents could still arise around a genuinely novel formulation, manufacturing process, package, dosage form, or delivery system.

When does PREVACID 24 HR lose exclusivity?

The relevant active-ingredient exclusivity has already expired. Lansoprazole is an established generic proton pump inhibitor, and multiple manufacturers supply prescription lansoprazole products.

The remaining commercial protections are primarily:

• Brand trademark rights.
• Consumer awareness.
• Retail placement.
• Packaging and trade dress.
• Product-specific formulation know-how.
• Manufacturing scale.
• Distribution agreements.
• Potentially narrow patents on later-developed technologies.

The product therefore has low composition-of-matter exclusivity risk but meaningful execution barriers. A generic or private-label entrant can compete on price, but it must still meet the product’s delayed-release performance and preserve stability through the labeled shelf life.

Which companies are challenging or competing with PREVACID 24 HR?

Competition comes from both lansoprazole products and alternative proton pump inhibitors.

Competitor category	Examples	Competitive effect
OTC lansoprazole	Store-brand and generic-equivalent products	Direct price competition
OTC omeprazole	Prilosec OTC and private-label products	Strong category substitute
OTC esomeprazole	Nexium 24HR and private-label products	Premium branded substitute
OTC famotidine	PEPCID and private-label products	Different mechanism and faster symptom positioning
Antacids and alginates	Calcium carbonate, magnesium products, alginate formulations	Immediate-relief alternative

Lansoprazole competes on once-daily dosing and established consumer familiarity. Omeprazole and esomeprazole have broader retail penetration in many channels. Famotidine competes through perceived speed of relief and use for intermittent symptoms.

What formulation patents could create new commercial opportunities?

New patent value would likely come from a technical improvement rather than lansoprazole itself. The most commercially relevant claim categories are:

Improved delayed-release systems

A sponsor could pursue claims covering:

• Multiparticulate pellets with defined coating thickness.
• Narrow acid-stage dissolution limits.
• Rapid intestinal release after a specified pH transition.
• Reduced inter-pellet variability.
• Moisture-resistant enteric coatings.
• Low-temperature coating processes.

Alternative dosage forms

Potential products include:

• Orally disintegrating tablets.
• Sprinkle capsules.
• Sachets containing enteric-coated granules.
• Chewable delayed-release tablets.
• Unit-dose stick packs.
• Pediatric or geriatric-friendly multiparticulates, subject to regulatory positioning.

The key technical issue is that a convenient dosage form cannot compromise the acid protection required for lansoprazole. A chewable or orally disintegrating product requires careful protection of the enteric particles during compression, mastication, and storage.

Excipient-specific patent strategies

Patents may be defensible where they claim a narrow combination of:

• A particular enteric polymer.
• A defined protective subcoat.
• A low-moisture excipient system.
• A specific plasticizer concentration.
• A controlled pellet-size distribution.
• A defined dissolution profile.
• An oxygen- or moisture-barrier package.

Broad claims to ordinary excipients are less likely to provide durable protection because many of the materials are established pharmaceutical ingredients and are listed in FDA’s Inactive Ingredient Database (FDA, 2024c).

How strong is the patent estate for PREVACID 24 HR?

The legacy patent estate is weak as a barrier to generic active-ingredient competition. The commercial estate is stronger in operational areas:

Asset	Relative strength
Lansoprazole molecule	Low
Original prescription indication	Low
Basic delayed-release capsule	Low to moderate
Specific pellet-coating process	Moderate if narrowly claimed
Consumer brand and trademark	Moderate to strong
Retail distribution	Moderate
Manufacturing know-how	Moderate
Novel ODT, sachet, or sprinkle platform	Potentially moderate to strong
Current Orange Book blocking position	Limited for the OTC product

A new entrant should not assume that the absence of active molecule patents means simple product substitution. Enteric coating reproducibility, impurity control, and packaging performance can determine whether a product passes development and commercial-scale testing.

What excipient strategies offer the best commercial opportunity?

1. Cost-reduction strategy

The most immediate opportunity is a lower-cost equivalent capsule using qualified suppliers for:

• Enteric polymer.
• Sugar spheres.
• Hypromellose.
• Plasticizer.
• Capsule shells.
• Desiccant and barrier packaging.

Cost reduction must preserve coating efficiency and minimize batch rejection. A cheaper polymer that requires higher coating weight may eliminate the expected savings.

2. Clean-label strategy

Potential consumer claims could include:

• No artificial color.
• Titanium-dioxide-free capsule shell.
• Reduced excipient count.
• Plant-based capsule shell.
• Lower-sugar or sugar-free pellet platform.

These claims require careful substantiation and may alter moisture uptake, shell performance, or pellet manufacture. A vegetarian HPMC capsule is commercially attractive but may have different oxygen and moisture transmission properties than gelatin.

3. Stability strategy

A high-value technical program would target improved stability in hot and humid markets. Relevant measures include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Low-moisture excipient grades.
• Reduced residual water.
• Oxygen-scavenging packaging.
• Improved subcoat protection.

Stability improvements can support longer shelf life, fewer complaints, and geographic expansion into markets with difficult distribution conditions.

4. Convenience strategy

A sprinkle capsule or orally disintegrating product could address consumers who have difficulty swallowing capsules. A sachet or stick pack could improve portability and support travel-oriented marketing.

These products may qualify for 505(b)(2) development if they introduce a meaningful dosage-form change. They would still require evidence supporting dose delivery, dissolution, stability, and appropriate labeling.

What manufacturing and intellectual-property barriers exist?

Manufacturing is the main practical barrier. A sponsor needs reproducible fluid-bed coating, pellet-size control, low-defect encapsulation, and validated acid-stage dissolution.

Important process controls include:

• Drug-layer uniformity.
• Pellet moisture.
• Coating weight gain.
• Spray rate.
• Inlet and product temperature.
• Atomization conditions.
• Agglomeration control.
• Capsule fill-weight variation.
• Enteric film integrity.
• Dissolution after accelerated aging.

Potential manufacturing patents may cover equipment configurations, coating sequences, or process parameters. Trade secrets can be more valuable than patents where the competitive advantage lies in process capability rather than a readily detectable product feature.

Geographic coverage also matters. A U.S. OTC product may face different regulatory and patent conditions in Canada, the European Union, Japan, and emerging markets. Lansoprazole is generic internationally, but national rules for OTC proton pump inhibitors, excipient labeling, capsule materials, and health claims vary.

What generic launch scenarios exist for PREVACID 24 HR?

Scenario 1: Low-cost private label

A retailer launches a 15 mg delayed-release lansoprazole capsule using an established multiparticulate platform. The strategy competes on price and store placement. Regulatory execution and supply reliability are the main risks.

Scenario 2: Brand-equivalent OTC challenger

A consumer-health company launches a branded product with similar dosing but differentiated packaging, adherence messaging, and distribution. The product competes against PREVACID 24 HR without requiring a novel active ingredient.

Scenario 3: Convenience formulation

A sponsor develops an orally disintegrating or sprinkle formulation. This creates more differentiation but increases development, regulatory, and patent costs.

Scenario 4: Clean-label premium product

A sponsor removes selected colorants, changes the capsule shell, or reduces excipient complexity. The commercial upside depends on whether consumers will pay a premium in a crowded acid-reducer category.

Scenario 5: International expansion

A manufacturer uses the same pellet platform across multiple countries, adapting labels and pack sizes. The opportunity is strongest where OTC proton pump inhibitor access is expanding and branded competition is less entrenched.

What revenue exposure does PREVACID 24 HR create?

Revenue exposure is concentrated in the OTC acid-reducer category rather than in prescription lansoprazole. The principal drivers are:

• Brand share within OTC proton pump inhibitors.
• Retailer placement.
• Promotional pricing.
• Private-label substitution.
• Seasonal heartburn demand.
• Consumer switching to omeprazole, esomeprazole, or famotidine.
• Availability of large-count bottles and multipacks.

Because the active ingredient is generic, pricing pressure is structurally high. The stronger assets are brand recognition, shelf visibility, formulation reliability, and channel access. A manufacturer with an existing capsule-coating platform can pursue the category with lower incremental manufacturing cost than a company building the technology from scratch.

Key Takeaways

• PREVACID 24 HR is a 15 mg delayed-release lansoprazole capsule for OTC frequent heartburn.
• Its commercial performance depends on enteric coating, protective subcoats, stability, packaging, and retail execution.
• Lansoprazole’s core composition and legacy prescription exclusivity no longer provide a meaningful barrier to generic competition.
• PREVACID 24 HR is not primarily protected by an active Orange Book patent position because it is an OTC product.
• The best excipient opportunities involve polymer substitution, lower-moisture systems, clean-label capsules, improved barrier packaging, and alternative dosage forms.
• A private-label capsule is the lowest-risk launch strategy.
• Orally disintegrating, sprinkle, and sachet products offer greater differentiation but require more extensive formulation and regulatory work.
• Manufacturing know-how, coating reproducibility, and supply-chain control are likely to matter more than legacy molecule patents.
• Biosimilar risk is not relevant because lansoprazole is a chemically synthesized small molecule. Generic substitution is the relevant competitive risk.
• New patent value would most likely arise from narrowly defined coating systems, dissolution profiles, manufacturing processes, or differentiated dosage forms.

FAQs

Is PREVACID 24 HR a generic drug?

PREVACID 24 HR is a branded OTC lansoprazole product. Lansoprazole itself is available from multiple generic manufacturers, but the PREVACID trademark and product presentation remain brand assets.

Can a company make an OTC lansoprazole capsule without licensing Takeda?

A company can generally develop and market its own lansoprazole product without licensing the PREVACID brand, provided it satisfies applicable FDA requirements and avoids protected trademarks, trade dress, patents, and confidential manufacturing information.

Which excipient is most critical to lansoprazole product performance?

The enteric polymer system is the most critical because it controls protection from gastric acid and release in the intestine. The protective subcoat and moisture-control strategy are also important.

Is a vegetarian PREVACID 24 HR substitute commercially feasible?

Yes. A vegetarian HPMC capsule or alternative dosage form is technically feasible, but the sponsor must confirm equivalent stability, moisture protection, dissolution, and consumer labeling performance.

Does PREVACID 24 HR face biosimilar competition?

No. Biosimilars apply to biological products. PREVACID 24 HR contains lansoprazole, a small-molecule active ingredient, so the relevant competition comes from generic and private-label drug products.

References

1. U.S. Food and Drug Administration. (2024a). PREVACID 24HR: Lansoprazole delayed-release capsule, 15 mg: Drug facts and prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024c). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (2024d). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters and monographs relevant to delayed-release oral dosage forms. USP.